Treatment in Seroconversion Maintains HIV-Specific Immune Responses Similar to Long-Term Slow Progressors
Recent studies by Hocqueloux et al suggest that long-term control of viraemia is possible after discontinuation of prolonged ART initiated at seroconversion.1 This study compared a cohort of 15 long-term non-progressors (LTNPs) with spontaneously controlled viraemia with a cohort of 20 long-term treated HIV-1 seroconverters (LTTS), all of whom started ART at the time of seroconversion resulting in ART-induced controlled viraemia.2
LTNPs were defined as having an absence of clinical progression with no CD4 T cell and without using treatment. They have controlled viraemia (are "elite controllers") and low viral reservoirs.
Immunovirological parameters defined for this study included:
Inclusion criteria of the two study groups included:
Study participants were matched in terms of gender, age, ethnicity, transmission route, CD4 count, viral load and cell-associated DNA and RNA. The only significant difference (p=0.06) was between CD4/CD8 T-cell ratios.
Results of the study suggest comparable levels of highly polyfunctional HIV-1 specific CD4+ and CD8+ T cells in both LTTS and LTNPs. Polyfunctional T-cell profiles and low viraemia in the presence/absence of ART were seen in both groups. There was a trend towards a higher magnitude and breadth of HIV-1 specific CD8+ T cells in LTNPs compared to LTTS which is thought to have been driven by a response against the GAG proteins.
The study concluded that prolonged ART initiated at the point of HIV seroconversion is associated with immuno-virological features which resemble those of HIV-1 LTNPs.
Links to external websites are current at time of posting but not maintained.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)